VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

• Conditions: Macular Degeneration

• Registration Number: NCT01655589
• Lead Sponsor: Institute of Vision, Brasil

Brief Summary

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Status Verified: 2012-07
• Study First Submitted: 2012-07-31
• Study First Submitted QC: 2012-07-31
• Last Update Submitted: 2012-07-31
• Study First Posted: 2012-08-02
• Last Update Posted: 2012-08-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• Diagnosis of neovascular age-related macular degeneration
• Visual acuity better than 20/400
• Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
• Follow-up period of at least six months

Exclusion Criteria

• Choroidal neovascularization secondary to any other cause than age-related macular degeneration
• Eyes with polypoidal choroidal vasculopathy
• Eyes previously submitted to posterior vitrectomy
• Other diseases that could affect visual acuity

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Institute of Vision; 🇧🇷 Belo Horizonte, MG, Brazil